2009至2017年医疗保险优势计划参保者中乳腺癌大分割放射治疗的使用与支出
该研究基于2009至2017年私人雇主保险理赔数据,回顾性分析医疗保险优势计划中接受肿块切除术后全乳放疗的早期乳腺癌女性,比较大分割全乳放疗(HF-WBI)与常规分割全乳放疗(CF-WBI)的使用与支出。共9957例接受HF-WBI,18920例接受CF-WBI;HF-WBI使用随时间大幅增加并超过CF-WBI成为主导形式,保险方支付的放疗支出HF-WBI显著低于CF-WBI(调整差值4113美元,95%CI 4030-4197美元)。
要点
- HF-WBI使用随时间大幅增加,已超过CF-WBI成为主导放疗形式。
- 保险方支付的放疗支出HF-WBI较CF-WBI显著降低,调整差值4113美元(95%CI 4030-4197美元)。
- HF-WBI患者自付支出较CF-WBI平均少426美元,美国各州HF-WBI与CF-WBI费用比值存在地理差异(范围0.41-0.87)。
核心结论
- 在医疗保险优势计划乳腺癌参保者中,HF-WBI使用随时间大幅增加,已超过CF-WBI成为主导放疗形式。
- HF-WBI的临床采用速度超过任何持续的费用下降,尽管美国各州间这一较短放疗疗程的费用存在广泛差异。
- 随着医疗保险优势计划参保人数持续扩大,识别HF-WBI使用的驱动因素和费用差异来源将有助于指导向医疗保险受益人提供的癌症照护质量。
研究设计与样本
- 回顾性分析,使用私人雇主保险理赔数据,对2009至2017年医疗保险优势计划参保者进行汇总横断面评估。
- 研究人群为接受肿块切除术和全乳放疗的早期乳腺癌女性医疗保险优势计划参保者。
- 共9957例女性接受HF-WBI,18920例接受CF-WBI。
主要发现
- 年龄较大、住所距治疗机构较远、居住社区大学毕业生比例较高与HF-WBI使用增加相关。
- 保险方支付的放疗支出HF-WBI显著低于CF-WBI,调整差值4113美元(95%CI 4030-4197美元)。
- HF-WBI患者自付支出较CF-WBI平均少426美元。
- 美国各州间HF-WBI相对于CF-WBI的费用比值存在地理差异(范围0.41-0.87)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Technology advances in cancer care have paralleled rapidly increasing expenditures in radiation therapy. The use and costs of shorter cancer radiation therapy offer potential utility in clinical practice. We evaluate use and expenditures of Medicare Advantage (MA) beneficiaries receiving hypofractionated whole breast irradiation (HF-WBI) compared with conventionally fractionated whole breast irradiation (CF-WBI) in the United States and examine the relationship of patient characteristics with HF-WBI use. METHODS AND MATERIALS: We performed a retrospective analysis of radiation therapy in MA beneficiaries using private employer-sponsored insurance claims for a pooled cross-sectional evaluation from 2009 to 2017. The study population included female MA beneficiaries with early-stage breast cancer treated with lumpectomy and whole breast irradiation. RESULTS: A total of 9957 women received HF-WBI, and 18,920 received CF-WBI. Older age, greater distance from home to treatment facility, and a higher proportion of college graduates in the community of residence were associated with increased HF-WBI use. Mean insurer-paid radiation therapy expenditures were significantly lower for HF-WBI versus CF-WBI (adjusted difference, $4113; 95% CI, $4030-$4,197). Mean patient out-of-pocket expenditure for HF-WBI was $426 less than that of CF-WBI. Across US states, geographic variation existed in the ratio of costs for HF-WBI relative to CF-WBI (range, 0.41-0.87). CONCLUSIONS: HF-WBI use among MA beneficiaries with breast cancer has dramatically increased over time, surpassing CF-HBI as the dominant form of radiation therapy. HF-WBI clinical adoption has outpaced any continual cost decrease, despite wide variation across US states for this shorter radiation therapy treatment. As MA enrollment continues to expand, identifying the drivers of HF-WBI use and the sources of variation in costs of HF-WBI will help direct the quality of cancer care delivered to Medicare beneficiaries.
引用
- Saulsberry L, Liao C, Huo D, et al. Expenditures and Use of Hypofractionated Radiation Therapy Treating Breast Cancer Among Medicare Advantage Enrollees, 2009 to 2017. Adv Radiat Oncol. 2024. PMID: 39176100. doi:10.1016/j.adro.2024.101568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。